Spermosen’s team has a strong commitment to improving the quality of life for all those who live affected by infertility and involuntary childlessness. The mission is to support patients to achieve successful treatment by providing innovative diagnostic and treatment solutions for assisted reproduction.
Tore Duvold holds a PhD degree in bioorganic chemistry from Université Louis Pasteur in France. He is seasoned biotech entrepreneur and pharma executive renowned for seamlessly integrating science and business to drive innovations in medicine and healthcare. His expertise spans diverse therapeutic areas, encompassing inflammation, dermatology, nephrology, oncology, stroke, cardiovascular disease and anti-infectives. Proficient in drug discovery, clinical development, CMC, regulatory affairs, corporate governance, M&A, business development and financing, he brings a people-oriented approach, innate curiosity and a talent for fostering collaboration and effective communication. His track record includes successfully establishing new companies and new projects, securing financing, M&A, advancing drug candidates through clinical phases and forging impactful international partnerships.
Tore Duvold has held several executive positions including SVP and head of research, early development and patent at LEO Pharma, CEO and co-founder of Aker Biopharma, CEO of Coegin Pharma, CEO of Edvince and EVP and later CEO of Innovation Fund Denmark. He is also associated partner at Copenhagen Institute for Futures Studies.
Employee since: 2024
Ulrik Nilsson holds a Diploma in Management, Business Administration and Management, at Henley Business School, Master of Science in International Business Administration and Economics from the School of Economics and Management, Lund University and technical college graduate in energy technology.
Ulrik has more than 20 years of experience from senior finance positions in multinational global medical technology companies, such as Gambro and Baxter International Inc., and has worked with all areas of the business. Ulrik came from Precise Biometrics AB, where he was CFO. In addition to finance, Ulrik has been responsible for Investor Relations, IT and HR in previous roles.
Employee since: 2021
Holdings in Spermosens
Shares: 25 400 006
Options TO3: 14 371 432
Options TO4: 14 371 432
Dr. Jae Y. Shin har över 20 års erfarenhet inom området biosensorer, biofysik och biokemi. Dr. Jae Y. Shin har en bakgrund som inkluderar många positioner inom medicinteknikbolag och forskningsinstitutioner, såsom University of California, Berkeley, Ludwig-Maximilians-Universität München, Max Planck Institute of Biochemistry och Lunds universitet.
Employee since: 2023
Holdings in Spermosens
Shares: 0
Options: 0
Employee since 2024
Holdings in Spermosens
Shares: 0
Options: 0
Callum holds a Masters in Medicinal Chemistry from the University of Leeds and has worked in pharmaceutical and medtech industries for over 6 years. Callum has acquired extensive experience in manufacturing, supply and QA/RA and held a number of exciting and challenging positions including as a Global Project Lead for GSK.
More recently, he worked as Head of QA/RA at a UK start up where he implemented an ISO 13485 certified QMS, led various aspects of the manufacturing and supply operations and played an integral part of taking a product through development into the market.
Panchami holds Masters in biotechnology from Amity University, Mumbai.
She has over 3+ years of experience in Recombinant DNA proteins, upstream and downstream processing of proteins.
Panchami has acquired experience in manufacturing and development of Invitro diagnostic kits and products.
She has held a challenging position of Management Representative as Quality Assurance head implementing ISO 13485 in the organization.
Jaime Castillo-León studied chemistry at the Universidad Industrial de Santander. Jaime holds a Ph.D. in electrochemistry from Lund University. He has more than 15 years of industrial and academic experience designing and fabricating electrochemical and optical biosensors, besides solar energy devices. He has held Director and Managerial offices in two Swedish SMEs in the fields of biomedical and solar energy, as well as the position of Associate Professor at DTU Nanotech, Technical University of Denmark.
Chairman of the board
Board member since: 2024
Holdings in Spermosens
–
Ulrik Spork har en stark bakgrund inom institutionella investeringar och har innehaft befattningar som Managing Partner och Senior Partner på Novo Holdings. Hans ansvar har inkluderat att övervaka Principal Investments, Novo Growth Equity och Novo Ventures. Sedan 2016 har han varit ordförande för Danish Growth Capital (Dansk Vækstkapital II/III). Utöver riskinvesteringar har Ulrik även en gedigen erfarenhet från SME-styrelser inom medicinteknik och life science och har varit ordförande i flera startup-bolag.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2019
Born: 1967
Main occupation: Embryologist and Unit Manager, Laboratory, Reproductive Medicine Centre, Skåne University Hospital
Holdings in Spermosens
–
Dr. Ingela Liljeqvist Soltic arbetar för närvarande som embryolog och enhetschef för laboratorie- och vävnadsinrättning vid Reproduktionsmedicinskt centrum (RMC) vid Skånes Universitetssjukhus. Ingela har en BSc i Biomedical Laboratory Technology från Lunds universitet och en PhD i Biomedical Science. Ingela har tidigare arbetat som embryolog vid IVF Clinic Cura Öresund och på läkemedelsföretaget Merck. Ingela har lång erfarenhet från IVF och fertilitetsfrågor.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2022
Main occupation: Senior Vice President och Global Head, Reproductive Medicine Maternal Health, RMMH, Ferring Pharmaceuticals A/S.
Holdings in Spermosens
–
Christina Östberg Lloyd är idag grundare av och VD i Care & Communication AB, verksamt inom Life Science med fokus på strategi och business management, ledarskap, kommunikation samt medical- och scientific affairs. 25 års erfarenhet av big pharma som Ferring och Novo Nordisk och även CEO över ett SME, femtechbolaget Pharmiva som börsnoterades under hennes ledning. Fram till nyligen en globalt ledande position på Ferring Pharmaceuticals A/S som Senior Vice President och Global Head, Reproductive Medicine Maternal Health, RMMH. Christina är M.D. Specialist inom gynekologi och obstetrik med fokus på reproduktionsmedicin, avseende både manlig och kvinnlig infertilitet.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2020
Born: 1976
Main occupation: VP Product Development & Commercial Rx, Orifarm Healthcare
Holdings in Spermosens (through company and privately)
Shares: 395 132
Søren Melsing Frederiksen innehar för närvarande positionen som Vice President, Product Development and Commercial Rx, ORIFARM GROUP A/S. Søren innehar en B.A.Sc inom Applied Science och en master i läkemedelsutveckling. Søren var tidigare VP Sales & Marketing in Galenica AB och innan dess har han haft ett flertal positioner inom LEO Pharma och som kommersiellt ansvarig för Norden på Aspen Pharma. Søren har en lång erfarenhet inom marknadsföring och försäljning samt hela värdekedjan i läkemedelsbranschen.
Other current assignments: Styrelseledamot i VBM Ejendomsselkabet af 2007 Aps och StenoCare A/S. Styrelseledamot och VD i SML Holding ApS.
Independent in relation to the company and company management and in relation to the company’s major shareholders.
Board member
Board member since: 2018
Born: 1991
Main occupation: CEO Nested Bio AB
Holdings in Spermosens (through company and privately)
Shares: 1 637 764
Kushagr Punyani är grundare av Bolaget och har varit CSO-konsult för Bolaget fram till mars 2024. Kushagr innehar en licentiatexamen i engineering, microfluidic technology, från Lunds universitet. Från sina studier i Indien tillsammans med professor Sudha Srivastava, lade Kushagr grunden för Bolagets teknologi. Kushagr har även varit med och grundat ett flertal bolag som utvecklar nya teknologier inom medtech/läkemedel.
Other current assignments: Styrelseledamot i Prolevi Bio AB och i Diagonal Bio AB. Styrelseledamot och VD i Nested Bio AB.
Independent in relation to the company and company management. Innehavare av 4% av aktierna i Bolaget.
The collaboration with OIM Sweden (OIM) gives Spermosen access to a high-quality as well as flexible ISO13485-certified production capacity with experience in MedTech products. This enables production ramp up to meet Spermosen’s global demand. Through flexible production capacity, both quality and cost efficiency are ensured.
OIM is one of Sweden’s most innovative product development companies, with a concept that combines technical competence with people, innovation, and business acumen. OIM develops products for companies through an innovative approach to product development.
OIM’s ability to deliver is based on many years of experience in running complex product development projects. This, combined with deep technical know-how, enables OIM to meet innovation and development in new ways.
We are very pleased to have the honor of partnering with Spermosens who are developing a ground-breaking product that facilitates a choice that many struggle with. The opportunity to work with products that make a difference to people’s everyday lives is close to OIM’s heart.
– Arash Golshenas – Co-founder of OIM Sweden
Read more at: oimsweden.com
FlexMedical Solutions (FMS) have been engaged to partner with Spermosens in transitioning the JUNO-Checked cassette into a safe, reliable, and cost effectively produced product to contribute to improved diagnosis and treatment of male infertility.
“Having worked closely with the team at Spermosens we have a high degree of confidence in their team, technology and vision, and believe our unique skill set will complement that of Spermosens’s, to ensure rapid productization and on-time delivery of the JUNO-Checked System”
– says Kevin Fallon, CEO of FlexMedical Solutions
The team at FMS has been developing and manufacturing diagnostic products over the last 3 decades, and having worked with some of the biggest players in global diagnostics, they are well placed to know how to leverage their experience, inhouse technology and knowhow to deliver the right solutions for clients on time.
For more information: www.flexmedical-solutions.com
Stefan has a broad interdisciplinary background from his undergraduate studies at the nanoengineering program, and subsequent PhD studies in Physics at Lund University, Sweden. Throughout his PhD he focused on the application of nano and microstructures for the analysis of particles, for the investigation of biological samples. In addition Stefan has an extensive knowledge about miniaturization of diagnostic devices for lab-on-chip applications.
The profound technical background has been a perfect match for Spermosens, and has been an instrumental component when Stefan and his colleagues at the renowned patent law firm HØIBERG, have developed a viable IP strategy on behalf of Spermosens. The Spermosens and HØIBERG teams work closely together to maintain and develop the patent portfolio of Spermosens.
Peter Holm is a European Patent Attorney, Partner and Country Manager for Sweden at the patent law firm HØIBERG. Together with Stefan Holm Nygaard, Peter is acting as Spermosens’ strategic IP advisor. Peter has a PhDin Biochemistry and Biophysics from Karolinska Institutet, Sweden and has been working as a patent attorney at HØIBERG since 2006, assisting startup companies and individual researchers within the lifescience field, with the development of their IP strategy.
Marisa has a broad and deep scientific background from her undergraduate studies at University of Pavía, Italy and her PhD studies at Lund University, where she worked on the development of a new technologies for treatment of textile wastewater. As a European Patent Attorney, Marisa has extensive experience in areas ranging from diagnostic medical devices to biological pharmaceuticals and novel foods. Her broad scientific and legal background is a valuable asset for the management of Spermosens’ advanced interdisciplinary technology.
Read more at: hoiberg.com
